181038-01-7

Basic information

• Product Name: (+)-2(S)-[2-Cyano-5-(4-pyridylmethoxy)phenoxy]-2-(2-methylphenyl)acetic acid sodium salt
• Synonyms: RPR-117820A
• CAS NO: 181038-01-7
• Molecular Formula: C₂₂H₁₇N₂NaO₄
• Molecular Weight: 396.38159
• Mol File: 181038-01-7.mol

Chemical Properties

• CAS DataBase Reference: (+)-2(S)-[2-Cyano-5-(4-pyridylmethoxy)phenoxy]-2-(2-methylphenyl)acetic acid sodium salt(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-2(S)-[2-Cyano-5-(4-pyridylmethoxy)phenoxy]-2-(2-methylphenyl)acetic acid sodium salt(181038-01-7)
• EPA Substance Registry System: (+)-2(S)-[2-Cyano-5-(4-pyridylmethoxy)phenoxy]-2-(2-methylphenyl)acetic acid sodium salt(181038-01-7)

Safety Data

• Hazardous Substances Data: 181038-01-7(Hazardous Substances Data)

Upstream product

• 82380-18-5 2-fluoro-4-hydroxybenzonitrile 
• 529-20-4 2-methylphenyl aldehyde 
• 10445-91-7 4-(Chloromethyl)pyridine 
• 85589-35-1 o-methylmandelic acid 
• 181040-22-2 2-Fluoro-4-(pyridin-4-ylmethoxy)benzonitrile 

Relevant articles and documents

SUBSTITUTED PHENYL COMPOUNDS WITH A SUBSTITUENT HAVING A 1,3-BENZODIOXOLE RING

This invention is directed to compounds of formula I STR1 wherein R 1 is CN, CH 2 CN, CH=CHCN, CHO, or CH=CHCO. sub. 2 H;R 2 is aryl lower alkoxy, heteroaryl lower alkoxy, aryl lower alkylthio or heteroaryl lower alkylthio wherein each of the aryl and heteroaryl moieties is optionally substituted;R 3 is halogen;R 4 is optionally substituted aryl or optionally substituted heteroaryl;R. sup.5 is carboxy or an acid isostere; X is oxygen or sulphur; and n is zero or 1; or an N-oxide thereof, prodrug thereof solvate thereof, or pharmaceutically acceptable salt thereof, which compounds have endothelin antagonist activity. The invention is also directed to methods for preparing the compounds of formula I and their pharmaceutical use.

Substituted phenyl compounds with a substituent having a thienyl ring

This invention is directed to compounds of formula I wherein R1 is CN, CH2CN, CH=CHCN, CHO, or CH=CHCO2H; R2 is aryl lower alkoxy, heteroaryl lower alkoxy, aryl lower alkylthio or heteroaryl lower alkylthio wherein each of the aryl and heteroaryl moieties is optionally substituted; R3 is halogen; R4 is optionally substituted aryl or optionally substituted heteroaryl; R5 is carboxy or an acid isostere; X is oxygen or sulphur; and n is zero or 1; or an N-oxide thereof, prodrug thereof solvate thereof, or pharmaceutically acceptable salt thereof, which compounds have endothelin antagonist activity. The invention is also directed to methods for preparing the compounds of formula I and their pharmaceutical use.

Selective ET(A) antagonists. 5. Discovery and structure-activity relationships of phenoxyphenylacetic acid derivatives

The fifth paper in this series describes the culmination of our investigations into the development of a potent and selective ETA receptor antagonist for the treatment of diseases mediated by ET-1. Receptor site mapping of several ETA antagonists prepared previously identified a common cationic binding site which prompted synthesis of phenoxyphenylacetic acid derivative 13a, which showed good in vitro activity (IC50 59 nM, rat aortic ET(A)). Optimization of 13a led to the identification of 27b, which exhibited an IC50 of 4 nM. Although this did not translate into the expected in vivo potency, a compound of comparable in vitro activity, 27a (RPR118031A), showed a far better pharmacokinetic profile and in vivo potency (75 μmol/kg) and was duly proposed and accepted as a development candidate.